Plain-English translation of NCT06456463 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , combined with two other medications called and , can treat acute myeloid leukemia (AML) in adults who cannot tolerate standard intensive chemotherapy. The study has two parts: first, doctors will figure out the best dose of the medication to use, and then they will test that dose in two groups of patients with different genetic profiles. This treatment is designed specifically for people with AML that has a certain marker called CD123.
Many patients with AML are too old, too frail, or have other health problems that make standard intensive chemotherapy too dangerous. This trial aims to find an effective treatment option for these vulnerable patients who would otherwise have very few choices.
You likely qualify if…
You likely don't qualify if…
You will take the medication as an outpatient, likely at a cancer center, in combination with the two other drugs. The trial is divided into two phases: in the first phase, researchers determine the best dose, and in the second phase, you will receive that dose and be monitored to see how well the treatment works. You will have regular clinic visits for blood tests, physical exams, and monitoring of how you respond to the treatment.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States